Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015). (nature.com)

Authors: Jiao D … Liu Z Journal: Nature Communications Published: 2026-08-31 DOI: https://doi.org/10.1038/s41467-026-77041-x